Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1607-1614

  Hochster, Howard ^a   Weller, Edie ^a   Gascoyne, Randy D ^a   Habermann, Thomas M ^a   Gordon, Leo I ^a   Ryan, Theresa ^a   Zhang, Lijun ^a   Colocci, Natalia ^a   Frankel, Stanley ^a   Horning, Sandra J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; ALLERGY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; HEART DISEASE; HISTOLOGY; HUMAN; INFECTION; LUNG DISEASE; LYMPHOCYTOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; VINCRISTINE;

EID: 63749097149     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1561     Document Type: Article

References (30)

1. Ezdinli EZ, Harrington DP, Kucuk O, et al: The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 60:156-160, 1987
2. Steward WP, Crowther D, McWilliam LJ, et al: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma: A randomized prospective study with an assessment of prognostic factors. Cancer 61:441-447, 1988
3. Hagenbeek A, Carde P, Meerwaldt JH, et al: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 16:41-47, 1998
4. Hiddemann W, Griesinger F, Unterhalt M: Interferon alfa for the treatment of follicular lympho- mas. Cancer J Sci Am 4:S13-S18, 1998 (suppl 2)
5. Rohatiner A, Radford J, Deakin D, et al: A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 85: 29-35, 2001
6. Solal-Celigny P, Lepage E, Brousse N, et al: Doxorubicin-containing regimen with or without in- terferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16:2332-2338, 1998
7. Rohatiner A, Gregory W, Peterson B, et al: A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lym- phoma. J Clin Oncol 23:2215-2223, 2005
8. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
9. Maloney DG, Grillo-López AJ, Bodkin DJ, et al: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lym- phoma. J Clin Oncol 15:3266-3274, 1997
10. Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol 26:74-78, 1999
11. Berinstein NL, Grillo-Lopez AJ, White CA, et al: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular nonHodgkin's lymphoma. Ann Oncol 9:995-1001, 1998
12. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
13. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event- free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004
14. van Oers MH, Klasa R, Marcus RE, et al: Ritux- imab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
15. Hochster HS, Weller E, Gascoyne R, et al: Cyclophosphamide /fludarabine (CF) in advanced indolent lymphoma: Results from the E1496 Trial. J Clin Oncol 25:442s, 2007 (suppl; abstr 8004)
16. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
17. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the com
18. bination of cyclophosphamide, doxorubicin, vincris- tine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
19. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology study. J Clin Oncol 25:1986-1992, 2007
20. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and inter- feron in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
21. Ladetto M, De Marco F, Benedetti F, et al: Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high- risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004-4013, 2008
22. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludara- bine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
23. Ghielmini M, Schmitz SF, Cogliatti S, et al: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss
24. Group for Clinical Cancer Res (SAKK). J Clin Oncol 23:705-711, 2005
25. Gordan LN, Grow WB, Braylan RC, et al: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096-1102, 2005
26. Kahl BS, Williams M, Hong F, et al: Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). Blood 110:3420, 2007
27. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lympho- ma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006
28. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
29. Gopal AK, Press OW, Wilbur SM, et al: Ritux- imab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood
30. 112:830-835, 2008